#Tafamidis

In this letter we summarize our experience prescribing #tafamidis at @OHSUSOM @OHSUCardio in @JAMACardioGoal:summarize the out of pocket cost of tafamidis to patients and raise awareness about utilizing available resources

An interesting contrast of the @US_FDA label for tafamidis (in ATTR-CM) vs daratumumab (in AL). NYHA class IV were excluded in ATTRACT and NYHA class IIIb and IV excluded in

Enrico Ferro, MD

Would you care for a pragmatic understanding of cost-effectiveness for new #cardiovascular drugs? In our new @Heart_BMJ article, we use 3 case studies to clarify key concepts like cost-effectiveness &